Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with chronic kidney disease.
kidney outcomes trial, which involved more than 3500 individuals with chronic kidney disease and type 2 diabetes, randomized to once-weekly semaglutide or placebo plus standard care.
The trial achieved its primary endpoint with semaglutide 1 mg, producing a significant 24% relative risk reduction of kidney disease worsening, end-stage kidney disease, and death due to cardiovascular disease. The absolute risk reduction compared with placebo was 4.9% at 3 years.
Pratley added, “A large portion of patients I treat experience serious kidney complications and comorbidities, with some even requiring dialysis. Today’s decision by the FDA offers hope for the millions of adults living with both conditions and provides an additional treatment option, representing a significant advancement for my patients.”
Miriam E. Tucker is a freelance journalist based in the Washington, DC, area. She is a regular contributor to Medscape Medical News, with other work appearing in The Washington Post, NPR’s Shots blog, and Diatribe. She is on X: @MiriamETuckerAll material on this website is protected by copyright, Copyright © 1994-2025 by WebMD LLC. This website also contains material copyrighted by 3rd parties.
Chronic Kidney Failure Chronic Kidney Disease CKD Chronic Kidney Disease (CKD) Renal Failure Renal Insufficiency Kidney Insufficiency Kidney Failure Renal Impairment Renal Disease Kidney Disease Kidney Disorder Renal Disorder Nephropathy Kidneys
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Facial Fat Transfers: The New Trend for Ozempic UsersKya Odom, a Gen Z from Columbus, Ohio, opted for a facial fat transfer after losing significant weight. This procedure, similar to a BBL, uses liposuctioned fat to re-inflate patients' cheeks. The trend is on the rise due to the popularity of weight loss injectables like Ozempic, Wegovy, and Mounjaro, as many individuals experience facial volume loss after rapid weight loss.
Read more »
Ozempic, Wegovy and other new drugs are selected for Medicare's price negotiationsThe Biden administration says popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers.
Read more »
Ozempic: Weight-Loss Drug's Benefits And Risks Revealed in New StudyThe Best in Science News and Amazing Breakthroughs
Read more »
Oprah Winfrey Weight Loss: Star Talks Obesity, and Ozempic in New SpecialOprah Winfrey sat down with TODAY’s Al Roker to celebrate his 70th birthday and revealed the one thing in her life she would do differently if she could. Winfrey also touches on how “The Oprah Winfrey Show” would be different if it started today.
Read more »
Missing You Rotten Tomatoes Score RevealedThe new Harlan Coben adaptation 'Missing You' receives a mixed reception from critics on Rotten Tomatoes.
Read more »
Microdosing Ozempic for Weight Loss: A Risky Trend Gaining PopularityA new trend sees people microdosing Ozempic, a diabetes medication, for weight loss. While both Ozempic and Wegovy are approved for their respective purposes, microdosing Ozempic, using smaller doses than prescribed, is not approved by the FDA. Experts warn against this practice due to the lack of established guidelines and potential risks.
Read more »